Chromatin-binding proteins are critical regulators of cell state in haematopoiesis,. Acute
leukaemias driven by rearrangement of the mixed lineage leukaemia 1 gene (KMT2A r) or …

Targeting critical epigenetic regulators reverses aberrant transcription in cancer, thereby
restoring normal tissue function,–. The interaction of menin with lysine methyltransferase 2A …

The protein-protein interaction between menin and mixed lineage leukemia 1 (MLL1) plays
a critical role in acute leukemias with translocations of the MLL1 gene or with mutations in …

Menin inhibitors constitute a novel class of agents targeting the underlying biology of
nucleophosmin (NPM1) mutant and KMT2A (formerly known as MLL1) rearranged (KMT2Ar) …

Menin is a tumour suppressor protein whose loss or inactivation causes multiple endocrine
neoplasia 1 (MEN1), a hereditary autosomal dominant tumour syndrome that is …

Abstract Histone-lysine-N-methyltransferase 2A (KMT2A) is a central regulator of target
genes that drive leukemogenic transformation. KMT2A rearrangements (KMT2Ar) and …

Menin inhibitors are novel targeted agents currently in clinical development for the treatment
of genetically defined subsets of acute leukemia. Menin has a tumor suppressor function in …

Menin is the product of the tumor suppressor gene Men1 that is mutated in the inherited
tumor syndrome multiple endocrine neoplasia type 1 (MEN1). Menin has been shown to …

Abstract Treatment with Menin inhibitor (MI) disrupts the interaction between Menin and
MLL1 or MLL1-fusion protein (FP), inhibits HOXA9/MEIS1, induces differentiation and loss of …

In MLL1-rearranged AML (MLL1-r), the MLL1 fusion protein (MLLFP) causes dysregulated
expression of HOXA9, MEIS1, PBX3, MEF2C and CDK6 [1, 2]. HOXA9 and its co-factor …